A groundbreaking blood test for colorectal cancer screening could reshape early detection. Learn how this FDA-approved method ...

Background: Current guidelines for screening of colorectal cancer do not offer specific recommendations for cessation of antithrombotic agents prior to fecal occult blood test (FOBT). Aim ...

Discover how the FIT test is transforming colorectal cancer screening, reducing mortality rates and offering a more ...

Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and ...

[19] This study was limited by failure to establish the reliability of the bililabstix as a test for occult blood, failure to blind the test results, and retrospective patient classification.

Johns Hopkins Outpatient practices are open. If you have questions about your scheduled doctor’s appointment please check directly with your doctor’s office. Johns Hopkins Community Physicians’ ...

The company hopes that its noninvasive assay is easier to use than stool-based fecal occult blood tests (FOBTs), currently the mainstay for early detection, but it does not see it replacing ...

Under the agreement, Sysmex will distribute and service in Canada Sentinel Diagnostics' SentiFit 270 and SentiFit 800 analyzers for fecal immunochemical testing.

Breakthroughs in laboratory and data science are increasing interest in blood tests to screen for cancer, with colorectal ...

Other competition comes from alternative testing approaches, such as gold-standard colonoscopies, flexible sigmoidoscopies, fecal occult blood tests, liquid biopsies, and fecal immunochemical tests.